Dudediligence.

enGene Therapeutics Inc

ENGNNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Price
FilingsNewest: 10-Q, Quarterly reportSep 8 →InsidersNo open-market buys or sales.→HoldersBML 10.0%Siren 9.3%Perceptive 7.2%→Financing →PeersClosest companies: SNTI, RNAZ, DCOY→

From the filings

Figures

Net income
−$130.4Mlast 12 months
Operating cash flow
−$110.0Mlast 12 months
Cash and equivalents
$41.0Mat the last balance sheet
Shares outstanding
67.0M shareson issue
Every year and quarter →